Unfortunately, war is the daily media lead. We get the numbers of dead and injured for each conflict. You might consider those just injured as ‘lucky’ if you’re like me. Au contraire. Familiar issues are traumatic brain and spine injuries. Alongside lost limbs and wounds caused by bomb debris and emotional symptoms such as PTSD and depression that may persist for years, sometimes a lifetime. (Xaigham.com)
For life-saving technologies, war has unfortunately become a growth sector. I take no pleasure in saying that.
A sudden, traumatic blow to the spine (tSCI) can fracture, dislocate, crush or compress one or more of the vertebrae. A gunshot or knife wound that penetrates and cuts the spinal cord also can cause a spinal cord injury. Additional damage usually occurs over days or weeks.
The global Spinal Cord Trauma Treatment market was valued at US$ 2458.9 million in 2022 and is projected to reach US$ 3009.4 million by 2029, at a CAGR of 2.9% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The current Middle East conflict was not included. Unfortunately, those projected growth numbers could rise significantly.
While I am using the wars and conflicts as examples of the growth of the traumatic injury market, it was already significant and this is just the US.
- A recent estimate of the annual incidence of traumatic spinal cord injury (CCI) is approximately 54 cases per one million people in the United States.
- The estimated number of people with tSCI living in the United States is approximately 302,000 persons, ranging from 255,000 to 383,000 persons.
- The average age at injury has increased from 29 during the 1970s to 43 since 2015.
- Traumatic brain injury (TBI) is defined as an alteration in brain function or other evidence of brain pathology caused by an external force. Examples of TBI include falls, assaults, motor vehicle accidents and sports injuries.
The question arises: how is this issue addressed? There are myriad companies, large and small, looking for answers.
TORONTO and HAIFA, Israel, Jan. 05, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries.
How does it work? Stay with me; it’s pretty straightforward.
Part One: Active Ingredients
Exosomes: Exosomes, also known as extracellular vesicles, are nano-sized, naturally occurring particles in the body, secreted by cells. Exosomes, also known as extracellular vesicles, are nano-sized, naturally occurring particles in the body, secreted by cells. Can be administered non-invasively, intranasally
Part Two: Delivery
ExoTherapy: Exosomes, loaded with therapeutic molecules, cross the blood-brain barrier and reach cells and tissues for regeneration, rewiring and recovery.
Part Three: Effect
SiRNA-PTEN: The suggested PTEN inhibition-based therapeutic targets are nerve growth and regeneration after injury or damage, treatment of cardiac ischemia/reperfusion and associated disease, wound repair, and infertility.
The goal is to reverse this traumatic brain trauma as well as develop other health issues such as depression—no small accomplishment. The US FDA has granted NRX Orphan Drug Status.
The Orphan Drug Designation program provides orphan status to drugs and biologics for rare diseases that meet specific criteria. Orphan drug designation provides incentives, including:
- Tax credits for qualified clinical trials
- Exemption from user fees
- Potential for seven years of market exclusivity after approval
“Orphan-drug designation is expected to streamline our go-to-market, shorten our regulatory process, save the Company millions of dollars, and provide valuable market exclusivity. We appreciate the formal recognition of the potential impact of our therapy on the lives of patients suffering from acute spinal cord injuries,” said Dr. Shaltiel, CEO of NurExone Biologic, Ltd.
The Company also holds an exclusive worldwide license from Technion and Tel Aviv University for developing and commercializing the technology.
This technology is not only promising but appears well destined for success. In their totality, the current NRX out-front therapies could bring much relief to those seriously ‘injured’ patients who live with chronic pain and myriad challenges daily.
NurExome is a cutting-edge medical technology company. While trading has been modest, it paints a positive investment picture for the previously reasons stated. Will it pop tomorrow? No. That I can guarantee.
A savvy plan would to be to approach as a dollar-cost average investment. The deeper you dig, the more potential will become apparent.
Note Hyperlinks below.
| Stock stats Jan 5 2024 | |
| 52 Week Range | 0.1000 0.4200 |
| Volume | 7,000 |
| Avg. Volume | 4,511 |
| Market Cap | 14.475M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1100 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.01 |
| In-depth Corporate Presentation Litchfield Research |
Pegasus Resources Inc. (TSX-V: PEGA) is a diversified Junior Canadian Mineral Exploration Company focusing on North America’s uranium, gold and base metal properties.
The Athabasca Basin is a region in the Canadian Shield of northern Saskatchewan and Alberta, Canada. It is best known as the world’s leading source of high-grade uranium, and the area currently supplies about 20% of the world’s uranium.
PEGASUS as proxy for the ongoing volatility in the Uranium market
Pegasus has well represented in NE Athabasca Basin in Saskatchewan, with a resource estimate of over 200k tons which means about 535k pounds of uranium. Within the basin, PEGA holds:
• Wollaston Northeast: 7 claims, 34,721 ha
• Bentley Lake: 3 claims, 12,397 ha
• Mozzie Lake: 3 claims, 6,908 ha
• Pine Channel: 1 claim
The IEA World Energy Outlook predicts a 52% increase in electricity demand from 2020 to 2040, with a 75% increase predicted from 2020 to 2050.
An odd, yet bullish turn for uranium
Giant Cameco Corporation (CCJ) recently had a very large number of call options purchased that are out-of-the-money. This activity indicates an investor or group of investors are very bullish on the uranium mining company’s prospects. Investors may end up jumping on the bandwagon, even though the stock is already up over 15% in the last month.
As investors can see, the shares popped on significant volume over the last few days. Technically, the purchase of large numbers of out-of-the-money call options in major uranium shares of Cameco (CCJ) over the last few days, which has fueled a run in the sector.
Cameco Chart
Out of the money call options are purchased to potentially take leveraged advantage of a large perceived price rise.
The first tranche for 22,667 (call options) would have cost $3.173 million (i.e., 22,667 calls x $1.40 x 100), which is 224 times the regular open interest (amount of contracts normally held). The investor(s) was willing to pay this with the assumption that CCJ stock will keep rising quite significantly over the next 3 months. The strike price at $37.00 is 28.38% over today’s price. So the investors put up a substantial sum believing CCJ will move up 29% by Dec. 16.
The second tranche has a lower hurdle. The investor(s) believe the stock will rise over 7.6% from today to $31.00 per share. They likely paid $6.83 million for 22,774 call options at the $3.00 mid-price for the options. This resulted in 62 times the normal open interest in the stock. (Barchart)
Uranium has had a lot of ink lately as energy supply/demand roils. With situation in Europe as Russia threatens energy supply to Europe and other aggressions, the world is becoming more comfortable with Nuclear Energy as a clean and affordable power source, albeit years away.
That said, Bill Gates has been busy developing state-of-the-art and safe nuclear power. He is ready to build his first facility.
• Bill Gates’ TerraPower has chosen Kemmerer, Wyoming, a frontier-era coal town, as the site where the company will build its first demonstration nuclear power plant.
• The plant will cost about $4 billion, half coming from TerraPower and half coming from the United States government, the company said.
• Will operate the plant, which will play a role in the power company’s decarbonization strategy.
Rocky Mountain Power — a PacifiCorp division owned by Berkshire Hathaway Energy — Once built, the plant will provide a baseload of 345 megawatts, with the potential to expand its capacity to 500 megawatts.
Other Developments:
PEGA Article Notes
– Trading Volumes Up Over 1 million shares
– Japan & USA doubling down on nuclear
– Energy Prices up 400% in Europe
– Ready to start drilling (major catalyst)
PEGA is undoubtedly a low cost way to gain exposure to both Uranium, the Athabasca Basin and in the same breath as major producers. Investors by their purchases are showing the Company to be involved and a potential major growth vehicle going forward in the volatile energy debate.
Watching the shares is recommended. For risk oriented investors interested in the sector, a purchase should be contemplated.
Other Articles Supporting Nuclear
Why even environmentalists are supporting nuclear power today
https://www.npr.org/2022/08/30/1119904819/nuclear-power-environmentalists-california-germany-japan
Japan Restarting
Germany Keeping Nuclear Power
France Restarting Entire Nuclear Fleet
Sentiment Changing
Mathew Smith
-
Mathew Smith#molongui-disabled-link
-
Mathew Smith#molongui-disabled-link
-
Mathew Smith#molongui-disabled-link
-
Mathew Smith#molongui-disabled-link
All Articles
The latest
INVESTMENT: THIS AI FIRM JUST RELEASED SOME GAME-CHANGING NEWS
Alset Capital Inc. (TSXV: KSUM) : Innovative Advancements Together with Nvidia
Discover The Phillips Township Property from Golden Rapture (CSE:GLDR)
Subscribe
©2024 10xAlerts